Sorafenib
Sorafenib (Nexavar) is a kinase inhibitor used as part of systemic therapy for various advanced malignancies. This pharmaceutical agent targets specific proteins involved in tumour cell growth and blood vessel formation. One product is available, specifically covering film-coated tablets for integrated oncology management.
Key points
- Blocks kinase proteins that signal cancer cells to divide, while also limiting the new blood vessels tumours need to grow.
- Skin redness and tenderness on the palms or soles, along with fatigue and gastrointestinal discomfort, are commonly reported.
- Sudden changes in blood pressure or heart rhythm during treatment may mean the treatment plan needs to be adjusted.
What is Sorafenib?
Sorafenib is a molecularly targeted therapy categorized as a kinase inhibitor. It functions by inhibiting multiple enzymes on the surface and within cancer cells, slowing down their replication and growth while limiting the blood supply required for tumour progression.
What Sorafenib is used for
This medication is used in the treatment of Hepatocellular Carcinoma, Renal Cell Carcinoma, and Differentiated Thyroid Carcinoma. These conditions often involve complex cellular pathways that require continuous, targeted management to achieve disease stability.
How does Sorafenib work?
Sorafenib works by blocking kinases, which are proteins that signal cells to divide. By interfering with these signals and inhibiting the development of new blood vessels, the medication starves tumour cells of the nutrients they need to grow and multiply.
Sorafenib brands and forms
The primary form is the film-coated tablet, designed for oral administration. For patients seeking Oncology Support, understanding the distinction between brand-name formulations and generics is part of informed treatment planning. The single product listed is Nexavar.
Safety overview for Sorafenib
What to check before using this medicine
Ensure that all current health conditions are disclosed to a treating physician, particularly liver or kidney issues and heart rhythm abnormalities. Baseline tests and regular monitoring are standard practices to assess suitability and track systemic response during the course of treatment.
Possible reactions and tolerability
Common responses can include skin changes, such as redness or sensitivity on the palms and soles, fatigue, and gastrointestinal changes. Monitoring for elevated blood pressure or heart-related symptoms is standard during therapy, and changes to the treatment plan may be necessary based on clinical observations.
Interactions and health factors
Sorafenib may interact with other medications, particularly those metabolized by the liver or those that affect heart rhythm. Product labelling and verified clinical sources remain the correct references for specific contraindications, interactions and reactions.